The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
Fiona Simpkins
No relevant relationships to disclose
Aurea M. Flores
No relevant relationships to disclose
Christina Chu
No relevant relationships to disclose
Joseph A. Lucci
No relevant relationships to disclose
Jonathan S. Berek
No relevant relationships to disclose
George Coukos
No relevant relationships to disclose
John W. Bauman
Stock Ownership - GlaxoSmithKline
Sharon Cornell Murray
Stock Ownership - GlaxoSmithKline
Herbert Struemper
Stock Ownership - GlaxoSmithKline
Fiona Germaschewski
Stock Ownership - GlaxoSmithKline
Zdenka Jonak
No relevant relationships to disclose
Olivia S. Gardner
Stock Ownership - GlaxoSmithKline
John F Toso
Stock Ownership - GlaxoSmithKline